Eli Lilly is acquiring AtaiBeckley in a deal finalized on July 16, 2026. The $2.8 billion cash transaction represents a major push by the American pharmaceutical company to strengthen its neuroscience drug portfolio through the addition of psychedelic-based mental health therapies.

Eli Lilly agreed to pay $2.8 billion in cash upfront for AtaiBeckley, an American clinical-stage biopharmaceutical company focused on mental health treatments. The acquisition price amounts to $6.75 per share in cash, which is 26% higher than AtaiBeckley’s closing share price of $5.36 on the prior Wednesday. In addition to the upfront payment, the deal includes a potential additional payout of up to $1 billion, structured as milestone-based payments tied to the successful development and regulatory approval of AtaiBeckley’s drug candidates. This contingent sum could translate to an extra $2.50 per share if those milestones are achieved.

AtaiBeckley develops psychedelic treatments for mental health conditions, with its lead candidate, BPL-003, currently in Phase 3 clinical trials for treatment-resistant depression. BPL-003 is a nasal spray formulation related to dimethyltryptamine (DMT). If administered, the treatment is delivered in a clinical setting, where patients are monitored for approximately two hours following dosing.

Initial results from the Phase 3 trials for BPL-003 are expected in 2029. Beyond BPL-003, AtaiBeckley is developing other psychedelics for mental health disorders, including a compound related to MDMA.

The acquisition aligns with Eli Lilly’s strategic focus on expanding its neuroscience medicines. The company has signaled a shift in acquisition strategy, targeting later-stage assets more aggressively than it has historically pursued. This approach is part of a broader plan disclosed earlier by Eli Lilly to spend more than $10 billion in upfront payments—and potentially as much as $25 billion total—across eight acquisitions in 2026. The AtaiBeckley purchase constitutes one of those planned transactions.

Market reaction to the announcement was swift. AtaiBeckley shares rose more than 30% in premarket trading on July 16, 2026, reflecting investor confidence in the deal’s terms and the perceived value of the company’s pipeline.

The acquisition underscores a growing trend in the pharmaceutical industry toward exploring psychedelic compounds as viable treatments for mental health conditions, an area of high unmet medical need. Eli Lilly’s investment signals corporate validation of clinical-stage psychedelic therapies, particularly those approaching late-phase trials like BPL-003. With treatment-resistant depression affecting millions globally and current therapeutic options often inadequate, the potential approval of a new class of rapid-acting treatments could alter clinical practice.

Eli Lilly’s willingness to commit billions to a single neuroscience asset also reflects its broader ambition to dominate emerging therapeutic categories. The company, founded in 1875, has historically focused on diabetes and immunology but has increasingly diversified into brain health. By acquiring AtaiBeckley—which was formed in November 2025 through the merger of atai Life Sciences N.V. and Beckley Psytech Limited—Eli Lilly gains access not only to a near-term registrational candidate but also to a pipeline that includes MDMA-related compounds, positioning it at the forefront of a rapidly evolving field.